Medical devices specialist Stentys announced today that it has completed a GBP 9 million second round venture financing led by UK venture firm Scottish Equity Partners. Existing investor Sofinnova Partners followed on. Brian Kerr of Scottish Equity Partners will join the Stentys Board of Directors.
“This financing round will allow us to complete clinical trials and obtain the CE Mark for our drug-eluting, bifurcated stent, enabling interventional cardiologists to offer their patients the next generation of dedicated bifurcated-stenting procedures,” said Stentys’ CEO and co-founder, Gonzague Issenmann.
“Stentys has achieved a major breakthrough in terms of patient safety, ease of use for cardiologists, and clinical efficacy,” said Brian Kerr. “It has a high-calibre management team, and has made rapid progress towards obtaining regulatory approval. There is a $1 billion-plus market opportunity for its product, and we are confident that the company will deliver significant value.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
